Marti Technologies shares fall 2.34% after-hours as Phase 3 SELVA trial enrollment completed.
ByAinvest
Thursday, Aug 14, 2025 5:13 pm ET1min read
MRT--
Marti Technologies Inc. declined 2.34% in after-hours trading. The company announced that its Phase 3 SELVA trial evaluating QTORIN™ rapamycin for microcystic lymphatic malformations has completed enrollment, exceeding the target by over 25%, with top-line results expected in the first quarter of 2026. Additionally, top-line results for the Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations are on track for the fourth quarter of 2025. The company also plans to announce a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ platform candidate before year-end 2025.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet